1Raza A, Meyer P. Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastie syndromes. Blood ,2001,98:958-965.
2Strupp C, Germlng U, Aivado M, et al. Thalidomide for the treatment of patients with myelodysplastie syndromes. Leukemia,2002,16 : 1-6.
3张之南 忱悌.血液病诊断及疗效标准（第2版）[M].北京:科学出版社,1999.270-271.
4Kochendeffer JN, Kobayashi S, Wieder ED, et al. Loss of T-lymphocyte clonal dominance in patients with myelodysplastie syndrome responsive to immunosuppressian. Blood,2002,100:3639-3645.
5Stifter G, Heiss S, Gastl G, et al. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes:relationship to anemia and prognosis, Eur J Haematol,2005,75:485-491.
6Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti2 TNF2α inhibitor:implication for clinical use. Clin Immunol lm2 munopathol,1996,81:219-223.
